Cell-Free Circulating DNA Integrity Based on Peripheral Blood as a Biomarker for Diagnosis of Cancer: A Systematic Review
Authors:
Open Access
- 31 October 2017
- journal article
- review article
- Published by American Association for Cancer Research (AACR) in Cancer Epidemiology, Biomarkers & Prevention
- Vol. 26 (11) , 1595-1602
Abstract
Background: Cell-free DNA integrity (cfDI) has been identified as a potential diagnostic biomarker for different types of cancer, suggesting the importance of liquid biopsy. Methods: This systematic review aims to assess the diagnostic performance of cfDI in cancer. After an extensive search of literature published through February 28, 2017, 25 articles that included 40 studies were identified. The descriptions of all the studies were analyzed. The sensitivity, specificity, positive and negative likelihood ratios, diagnostic ORs, weighted symmetric summary receiver operating characteristic curve, and the area under the curve (AUC) of cfDI in these studies were calculated. Results: Aberrant results of cfDI were observed. Some studies observed an increased cfDI in cancer patients, while some studies confirmed a decreased cfDI compared with healthy or benign controls. Conclusions: This review suggests that cfDI is controversial as a blood-based biomarker of cancers, although the sensitivity and AUC were relatively high. Impact: cfDI shows heterogeneity between different studies; more perspective studies are needed to further assess its diagnostic performance, especially with other markers in combination. Cancer Epidemiol Biomarkers Prev; 26(11); 1595–602. ©2017 AACR.Keywords
Funding Information
- China Scholarship Council (201306090129)
This publication has 53 references indexed in Scilit:
- Plasma MicroRNA Panel for Minimally Invasive Detection of Breast CancerPLOS ONE, 2013
- Diagnostic relevance of plasma DNA and DNA integrity for breast cancerTumor Biology, 2013
- Circulating cell free DNA: Preanalytical considerationsClinica Chimica Acta, 2013
- Mobile Health Applications for the Most Prevalent Conditions by the World Health Organization: Review and AnalysisJournal of Medical Internet Research, 2013
- Multiparametric Analysis of Cell-Free DNA in Melanoma PatientsPLOS ONE, 2012
- Comparing the MicroRNA Spectrum between Serum and PlasmaPLOS ONE, 2012
- Circulating tumour markers can define patients with normal colons, benign polyps, and cancersBritish Journal of Cancer, 2011
- Cell-free nucleic acids as biomarkers in cancer patientsNature Reviews Cancer, 2011
- Higher Amount of Free Circulating DNA in Serum than in Plasma Is Not Mainly Caused by Contaminated Extraneous DNA during SeparationAnnals of the New York Academy of Sciences, 2006
- Increased Integrity of Free Circulating DNA in Sera of Patients with Colorectal or Periampullary Cancer: Direct Quantitative PCR for ALU RepeatsClinical Chemistry, 2006